Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Neonc Technologies, Inc.
Bristol-Myers Squibb
ImmunityBio, Inc.
University of Pittsburgh
Incyte Corporation
Toray Industries, Inc
Eli Lilly and Company
Molecular Templates, Inc.
Sumitomo Pharma America, Inc.
Fate Therapeutics
Incyte Corporation
Duke University
Five Prime Therapeutics, Inc.
MultiVir, Inc.